NASDAQ: NKTXNkarta Inc Stock
$2.30-0.09 (-3.77%)
Updated Aug 13, 2026
NKTX Price
$2.30
Fair Value Price
-$0.50
Market Cap
$164.74M
52 Week Low
$1.70
52 Week High
$3.72
P/E
-1.46x
P/B
0.66x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$117.32M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.36
Operating Cash Flow
-$93M
Beta
1.61
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
NKTX Overview
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NKTX's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -12.86% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
NKTX
Ranked#451 of 464
Ranked#451 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.71 | A | |
| $110.51 | A | |
| $10.90 | A |
Be the first to know about important NKTX news, forecast changes, insider trades & much more!
NKTX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NKTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NKTX ($2.30) is overvalued by 562.62% relative to our estimate of its Fair Value price of -$0.50 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
NKTX ($2.30) is not significantly undervalued (562.62%) relative to our estimate of its Fair Value price of -$0.50 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
NKTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NKTX due diligence checks available for Premium users.
Valuation
NKTX fair value
Fair Value of NKTX stock based on Discounted Cash Flow (DCF)
Price
$2.30
Fair Value
-$0.50
Undervalued by
562.62%
NKTX ($2.30) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NKTX ($2.30) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NKTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NKTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.46x
Industry
16.75x
Market
14.17x
NKTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.66x
Industry
5.71x
NKTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NKTX's financial health
Profit margin
Revenue
$0.0
Net Income
-$40.4M
Profit Margin
0%
NKTX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$337.6M
Liabilities
$89.9M
Debt to equity
0.36
NKTX's short-term assets ($188.05M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NKTX's short-term assets ($188.05M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NKTX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
NKTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$24.2M
Investing
$21.1M
Financing
$676.0k
NKTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NKTX vs Biotech Stocks
Nkarta Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.